IONIS-GCCRRx
Jump to navigation
Jump to search
Clinical data | |
---|---|
Other names | ISIS-426115; ISIS-GCCRRx |
Drug class | Antiglucocorticoid |
Identifiers | |
UNII |
IONIS-GCCRRx, also known as ISIS-426115, is an antiglucocorticoid which is under development by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) for the treatment of diabetes mellitus type 2.[1][2] It has also been under investigation for the treatment of Cushing's syndrome, but no development has been reported.[1] The drug is an antisense oligonucleotide against the glucocorticoid receptor.[1] As of December 2017, it is in phase II clinical trials for diabetes mellitus type 2.[1]
References
- ^ a b c d "IONIS GCCRRx". AdisInsight. Springer Nature Switzerland AG.
- ^ Chikara G, Sharma PK, Dwivedi P, Charan J, Ambwani S, Singh S (April 2018). "A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?". Indian Journal of Clinical Biochemistry. 33 (2): 121–131. doi:10.1007/s12291-017-0668-z. PMC 5891460. PMID 29651202.
Categories:
- Articles with short description
- Short description matches Wikidata
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Experimental diabetes drugs
- Antiglucocorticoids
- Antisense RNA
- Drugs with undisclosed chemical structures
- Experimental drugs
- Therapeutic gene modulation
- All stub articles
- Systemic hormonal preparation stubs